论文部分内容阅读
目的探讨阿德福韦酯联合苦参素治疗慢性乙型肝炎的临床疗效。方法选择我院2007年1月至2009年1月慢性乙型肝炎患者103例。随机分为治疗组和对照组。其中治疗组53例,对照组49例。对照组给予阿德福韦酯口服10mg/次,1次/d。治疗组口服阿德福韦酯10mg/次,1次/d,同时口服苦参素胶囊200mg/次,2次/d,苦参素胶囊24周后结束服用,单独服用阿德福韦酯。两组疗程均为48周。在治疗24周、治疗48周时检测两组患者的ALT恢复正常率、HbeAg/抗Hbe血清转换率、HBVDNA转阴率。结果治疗24周、治疗48周时,治疗组的HbeAg/抗Hbe血清转换率与对照组比较,差异有统计学意义(P<0.01);治疗24周、治疗48周时,治疗组的HBVDNA转阴率与对照组比较,差异有统计学意义(P<0.01)。结论阿德福韦酯联合苦参素治疗慢性乙型肝炎临床疗效显著,优于单独使用阿德福韦酯,值得临床借鉴。
Objective To investigate the clinical efficacy of adefovir dipivoxil and oxymatrine in the treatment of chronic hepatitis B. Methods A total of 103 patients with chronic hepatitis B from January 2007 to January 2009 in our hospital were selected. Randomly divided into treatment group and control group. 53 cases in the treatment group and 49 cases in the control group. The control group was given adefovir dipivoxil 10mg / time, 1 time / d. The treatment group oral adefovir dipivoxil 10mg / time, 1 time / d, at the same time oral matrine capsule 200mg / time, 2 times / d, matrine capsules taken after 24 weeks, taking adefovir dipivoxil alone. The two groups were treated for 48 weeks. In the treatment of 24 weeks, 48 weeks after treatment, ALT recovery rate, HbeAg / anti-Hbe serum conversion rate and HBVDNA negative rate were detected in both groups. Results After treatment for 24 weeks and 48 weeks, the HbeAg / anti-Hbe seroconversion rate in the treatment group was significantly different from that in the control group (P <0.01). After treatment for 24 weeks and 48 weeks, HBVDNA conversion Compared with the control group, the difference was statistically significant (P <0.01). Conclusion adefovir dipivoxil combined with oxymatrine treatment of chronic hepatitis B has a significant clinical effect, superior to adefovir dipivoxil alone, it is worth learning from.